SynthesisFrontiers in immunology2019
Distribution of Bacterial α1,3-Galactosyltransferase Genes in the Human Gut Microbiome.
Synthesis in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens.The Journal of clinical investigation · 2026Article
- From vector to allergen: exploring the immunology of tick-triggered α-Gal syndrome.Frontiers in immunology · 2026Review
- Enhanced Detection of αGal Using a Novel Monoclonal IgG1 Antibody: Comparative Evaluation with IgM Antibody [Clone M86].Journal of personalized medicine · 2025Article
- Genomic Analysis of Glycosyltransferases Responsible for Galactose-α-1,3-Galactose Epitopes inVaccines · 2025Article
- A Review of Alpha-Gal Syndrome for the Infectious Diseases Practitioner.Open forum infectious diseases · 2025Review
- IgG to Galactose-Alpha-1,3-Galactose: Impact of Alpha-Gal IgE Sensitization, Blood Type, and Tick Bites.Antibodies (Basel, Switzerland) · 2025Article
- Impact of Staphylococcus aureus colonization and skin abscesses on formation of human anti-αGal antibodies.Medical microbiology and immunology · 2025Article
- Alpha-gal syndrome and the gastrointestinal reaction: a narrative review.Frontiers in allergy · 2025Review
- Exploring the relationship betweenComputational and structural biotechnology journal · 2024Review
- The Tick Microbiome: The "Other Bacterial Players" in Tick Biocontrol.Microorganisms · 2024Review
- Review
- The α-Gal epitope - the cause of a global allergic disease.Frontiers in immunology · 2024Review
- Influence of microbiota-driven natural antibodies on dengue transmission.Frontiers in immunology · 2024Article
- The role of glycosylation in clinical allergy and immunology.The Journal of allergy and clinical immunology · 2024Review
- Th2-skewed T cells correlate with B cell response to α-Gal and tick antigens in α-Gal syndrome.The Journal of clinical investigation · 2023Article
- Microbiosis in lung allotransplantation and xenotransplantation: State of the art and future perspective.Health care science · 2022Review
- Functional characterization of α-Gal producing lactic acid bacteria with potential probiotic properties.Scientific reports · 2022Article
- The Quantification of IgG Specific to α-Gal Could Be Used as a Risk Marker for Suffering Mammalian Meat Allergy.Foods (Basel, Switzerland) · 2022Article
- The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration.Nature medicine · 2022Article
- Recently EvolvedFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because of a loss-of-function mutation in the GGTA1 gene, humans are unable to synthetize α1,3-Galactose (Gal) decorated glycans and develop high levels of circulating anti-α1,3-Galactose antibodies (anti-Gal Abs). Anti-Gal Abs have been identified as a major obstacle of organ xenotransplantation and play a role in several host-pathogen relationships including potential susceptibility to infection. Anti-Gal Abs are supposed to stem from immunization against the gut microbiota, an assumption derived from the observation that some pathogens display α1,3-Gal and that antibiotic treatment decreases the level of anti-Gal. However, there is little information to date concerning the microorganisms producing α1,3-Gal in the human gut microbiome. Here, available α1,3-Galactosyltransferase (GT) gene sequences from gut bacteria were selectively quantified for the first time in the gut microbiome shotgun sequences of 163 adult individuals from three published population-based metagenomics analyses. We showed that most of the gut microbiome of adult individuals contained a small set of bacteria bearing α1,3-GT genes. These bacteria belong mainly to the Enterobacteriaceae family, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.